Pazufloxacin mesilateCAS# 163680-77-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 163680-77-1 | SDF | Download SDF |
| PubChem ID | 6918232 | Appearance | Powder |
| Formula | C17H19FN2O7S | M.Wt | 414.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | T-3762; Pazufloxacin methanesulfonate; Pazufloxacin mesilate | ||
| Solubility | DMSO : 100 mg/mL (241.31 mM; Need ultrasonic) H2O : ≥ 100 mg/mL (241.31 mM) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O.CS(=O)(=O)O | ||
| Standard InChIKey | UDHGFPATQWQARM-FJXQXJEOSA-N | ||
| Standard InChI | InChI=1S/C16H15FN2O4.CH4O3S/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22;1-5(2,3)4/h4-5,7H,2-3,6,18H2,1H3,(H,21,22);1H3,(H,2,3,4)/t7-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Pazufloxacin mesilate Dilution Calculator
Pazufloxacin mesilate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4131 mL | 12.0656 mL | 24.1313 mL | 48.2625 mL | 60.3282 mL |
| 5 mM | 0.4826 mL | 2.4131 mL | 4.8263 mL | 9.6525 mL | 12.0656 mL |
| 10 mM | 0.2413 mL | 1.2066 mL | 2.4131 mL | 4.8263 mL | 6.0328 mL |
| 50 mM | 0.0483 mL | 0.2413 mL | 0.4826 mL | 0.9653 mL | 1.2066 mL |
| 100 mM | 0.0241 mL | 0.1207 mL | 0.2413 mL | 0.4826 mL | 0.6033 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pazufloxacin (T-3761) mesylate is a fluoroquinolone antibiotic. Target: Antibacterial Pazufloxacin (T-3761), a new quinolone derivative, showed broad and potent antibacterial activity. T-3761 showed good efficacy in mice against systemic, pulmonary, and urinary tract infections with gram-positive and gram-negative bacteria, including quinolone-resistant Serratia marcescens and Pseudomonas aeruginosa. The in vivo activity of T-3761 was comparable to or greater than those of ofloxacin, ciprofloxacin, norfloxacin, and tosufloxacin against most infection models in mice. The activities of T-3761 were lower than those of tosufloxacin against gram-positive bacterial systemic and pulmonary infections in mice but not against infections with methicillin-resistant Staphylococcus aureus [1]. T-3761 had a broad spectrum of activity and had potent activity against gram-positive and -negative bacteria. The MICs of T-3761 against 90% of the methicillin-susceptible Staphylococcus aureus, methicillin-susceptible and -resistant Staphylococcus epidermidis, and Clostridium spp. tested were 0.39 to 6.25 micrograms/ml. The MBCs of T-3761 were either equal to or twofold greater than the MICs. The 50% inhibitory concentrations of T-3761 for DNA gyrases isolated from E. coli and P. aeruginosa were 0.88 and 1.9 micrograms/ml, respectively [2].
References:
[1]. Fukuoka, Y., et al., In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother, 1993. 37(3): p. 384-92.
[2]. Muratani, T., M. Inoue, and S. Mitsuhashi, In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother, 1992. 36(10): p. 2293-303.
- Kadsulignan L
Catalog No.:BCN3627
CAS No.:163660-06-8
- Evofolin C
Catalog No.:BCN4695
CAS No.:163634-05-7
- Fmoc-D-Trp(Boc)-OH
Catalog No.:BCC3561
CAS No.:163619-04-3
- Kadsulignan N
Catalog No.:BCN3631
CAS No.:163564-58-7
- Vilazodone
Catalog No.:BCC2040
CAS No.:163521-12-8
- Vilazodone Hydrochloride
Catalog No.:BCC2041
CAS No.:163521-08-2
- Triptoquinonide
Catalog No.:BCN1724
CAS No.:163513-81-3
- Flufenamic acid
Catalog No.:BCC9162
CAS No.:530-78-9
- Fmoc-Met(O2)-OH
Catalog No.:BCC3531
CAS No.:163437-14-7
- 2',4'-Di-O-(E-p-coumaroyl)afzelin
Catalog No.:BCN6512
CAS No.:163434-73-9
- Stachybotrylactam
Catalog No.:BCN6967
CAS No.:163391-76-2
- FIIN-2
Catalog No.:BCC3974
CAS No.:1633044-56-0
- WIN 64338 hydrochloride
Catalog No.:BCC6914
CAS No.:163727-74-0
- Auristatin F
Catalog No.:BCC5522
CAS No.:163768-50-1
- YM 90709
Catalog No.:BCC7149
CAS No.:163769-88-8
- 7beta-Hydroxyrutaecarpine
Catalog No.:BCN6500
CAS No.:163815-35-8
- Salvianolic acid Y
Catalog No.:BCN8123
CAS No.:1638738-76-7
- Androstenediol-3-acetate
Catalog No.:BCC8829
CAS No.:1639-43-6
- 8(17),12E,14-Labdatrien-20-oic acid
Catalog No.:BCN7396
CAS No.:1639257-36-5
- 12E,14-Labdadien-20,8beta-olide
Catalog No.:BCN7395
CAS No.:1639257-37-6
- Kaempferol-3-O-(6''-O-cis-coumaryl)glucoside
Catalog No.:BCN1538
CAS No.:163956-16-9
- Longiferone B
Catalog No.:BCN7378
CAS No.:1639810-67-5
- Clerodenoside A
Catalog No.:BCN1725
CAS No.:164022-75-7
- LY 311727
Catalog No.:BCC7728
CAS No.:164083-84-5
Synthesis of uniform Ag nanosponges and its SERS application.[Pubmed:29763823]
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Aug 5;201:300-305.
With the aid of amino acid, various Ag nanostructures were successfully synthesized via the reaction between silver nitrate and hydrazine hydrate at room temperature. The as-prepared products were characterized by X-ray diffraction and scanning electron microscopy. It was found that the morphology of the as-prepared Ag products depended on the sorts of amino acid and solvents. The uniform Ag nanosponges could be obtained in glycol with aid of glycine. Using rhodamine 6G (R6G) as probe, the surface-enhanced Raman scattering (SERS) performance was also investigated, which showed that the uniform Ag nanosponges exhibited an intensive and enhanced Raman scattering. Pazufloxacin mesilate (PM) were detected conveniently using these uniform nanosponges as SERS substrates. The present work might afford some guidance for the rationally controllable synthesis of other metal nanomaterials.
Colorimetric recognition of pazufloxacin mesilate based on the aggregation of gold nanoparticles.[Pubmed:26774816]
Spectrochim Acta A Mol Biomol Spectrosc. 2016 Mar 15;157:244-250.
A novel colorimetric nanomaterial-assisted optical sensor for Pazufloxacin mesilate was proposed for the first time. Pazufloxacin mesilate could induce the aggregation of glucose-reduced gold nanoparticles (AuNPs) through hydrogen-bonding interaction and electrostatic attraction, leading to the changes in color and absorption spectra of AuNPs. The effect of different factors such as pH, the amount of AuNPs, reaction time and reaction temperature was inspected. Under the optimum condition, UV-vis spectra showed that the absorption ratio (A670/A532) was linear with the concentration of Pazufloxacin mesilate in the range from 9x10(-8) mol L(-1) to 7x10(-7) mol L(-1) with a linear coefficient of 0.9951. This method can be applied to detecting Pazufloxacin mesilate with an ultralow detection limit of 7.92x10(-9) mol L(-1) without any complicated instruments. Through inspecting other analytes and ions, the anti-interference performance of AuNP detection system for Pazufloxacin mesilate was excellent. For its high efficiency, rapid response rate as well as wide linear range, it had been successfully used to the analysis of Pazufloxacin mesilate in human urine quantificationally.
Gateways to clinical trials.[Pubmed:18193114]
Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55.
1-Octanol, 9vPnC-MnCc; Abiraterone acetate, Adalimumab, Adefovir dipivoxil, Alemtuzumab, Aliskiren fumarate, Aminolevulinic acid hexyl ester, Amlodipine besylate/atorvastatin calcium, Amrubicin hydrochloride, Anakinra, Aripiprazole, ARRY-520, AS-1404, Asimadoline, Atazanavir sulfate, AVE-0277, Azelnidipine; Bevacizumab, Bimatoprost, Boceprevir, Bortezomib, Bosentan, Botulinum toxin type B; Certolizumab pegol, Cetuximab, Clevudine, Contusugene ladenovec, CP-751871, Crofelemer, Cypher, CYT006-AngQb; Darbepoetin alfa, Desmopressin, Dexlansoprazole, DG-041; E-5555, Ecogramostim, Entecavir, Erlotinib hydrochloride, Escitalopram oxalate, Eszopiclone, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Falecalcitriol, Fampridine, Fesoterodine fumarate, Fingolimod hydrochloride; Gefitinib, Ghrelin (human), GS-7904L, GV-1001; HT-1001; Insulin detemir, ISIS-112989, Istradefylline; Laquinimod sodium, Latanoprost/timolol maleate, Lenalidomide, Levobetaxolol hydrochloride, Liposomal doxorubicin, Liposomal morphine sulfate, Lubiprostone, Lumiracoxib, LY-518674; MEM-1003, Mesna disulfide, Mipomersen sodium, MM-093, Mycophenolic acid sodium salt; Naptumomab estafenatox, Natalizumab; Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide; Paclitaxel nanoparticles, Paclitaxel poliglumex, Pasireotide, Pazufloxacin mesilate, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Pimagedine, Pimecrolimus, Pramlintide acetate, Prasterone, Pregabalin, Prulifloxacin; QAE-397; Rec-15/2615, RFB4(dsFv)-PE38, rhGAD65, Roflumilast, Romiplostim, Rosuvastatin calcium, Rotigotine, Rupatadine fumarate; Safinamide mesilate, SIR-Spheres, Sitagliptin phosphate, Sodium phenylacetate, Sodium phenylacetate/Sodium benzoate, Sorafenib, SSR-244738; Taribavirin hydrochloride, Taxus, Teduglutide, Tegaserod maleate, Telaprevir, Telbivudine, Tenofovir disoproxil fumarate, Tigecycline, Tiotropium bromide, Trabectedin, Travoprost, Treprostinil sodium; Ustekinumab; Valsartan/amlodipine besylate, Varenicline tartrate, Vildagliptin; Zofenopril calcium.
